Y-mabs announces fda clearance of ind for lutetium-177 labeled omburtamab antibody for adult indications

New york, oct. 26, 2020 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the u.s. food and drug administration (“fda”) has cleared the company's investigational new drug (“ind”) application for 177lu-omburtamab-dtpa for the treatment of b7-h3 positive central nervous system (“cns”) and leptomeningeal metastasis (“lm”) from tumors in adult patients.
YMAB Ratings Summary
YMAB Quant Ranking